Quoin Pharma rises on deal with Russia's Orpharm to sell rare disorder treatment

Quoin Pharmaceuticals

15/12/2021 16:28

** U.S. shares of Israel-based biotech co  QNRX.O  up ~2% at
$3.25
    ** Co enters into an exclusive distribution agreement with
Russian distribution co Orpharm LLC for lead product candidate,
QRX003, to treat Netherton Syndrome  urn:newsml:reuters.com:*:nGNX4VCnJ9 
    ** Netherton Syndrome caused by a type of gene mutation is a
rare, hereditary disorder that affects the skin, hair and immune
system
    ** Under the deal, Orpharm gains exclusive rights to
commercialize QRX003 in Russia and CIS countries
    ** QNRX is obligated to supply the product to Orpharm, upon
the receipt of regulatory approval
    ** Last month, co signed two commercial agreements for
QRX003 - with Genpharm Services for MENA region and with AFT
Pharma  AFT.NZ  for Australia and New Zealand  urn:newsml:reuters.com:*:nGNX5HSzQ9
 urn:newsml:reuters.com:*:nGNX5qsHNr 
    ** Including session's moves, stock fell 62.15% YTD

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))